These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27668546)

  • 21. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new abuse-deterrent opioid--Xtampza ER.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):77-8. PubMed ID: 27305067
    [No Abstract]   [Full Text] [Related]  

  • 23. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza
    Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB
    Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Extended-Release Oxycodone Administered through Enteral Tubes for the Management of Pain in Patients with Head and Neck Cancer: A Case Series.
    McGann M; Sacco A; Barnachea L
    J Pain Palliat Care Pharmacother; 2021 Dec; 35(4):240-245. PubMed ID: 34506216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain.
    Pergolizzi JV; Zampogna G; Taylor R; Raffa RB
    Expert Rev Neurother; 2015 Mar; 15(3):231-8. PubMed ID: 25683255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes.
    Clark AM; Pellock JM; Holmay M; Anders B; Cloyd J
    Epilepsy Behav; 2016 Apr; 57(Pt A):105-110. PubMed ID: 26943947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
    Davis MP
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):823-31. PubMed ID: 27253690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R
    J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
    Luo Z; Miao J; Shu S; Wang Y; Zhu X; Hu C; Shen Y
    Clin Drug Investig; 2020 Feb; 40(2):139-148. PubMed ID: 31679120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Eisenhauer TD; Matchett M; Heasley R; Morton T; Devarakonda K; Giuliani M; Young JL; Barrett T
    Drug Dev Ind Pharm; 2016 Jan; 42(1):157-165. PubMed ID: 26146769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
    Setnik B; Roland CL; Cleveland JM; Webster L
    Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.
    Kirkpatrick DL; Schmidt WK; Morales R; Cremin J; Seroogy J; Husfeld C; Jenkins T
    J Opioid Manag; 2017; 13(1):39-49. PubMed ID: 28345745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.
    Pergolizzi JV; Taylor R; Raffa RB
    Adv Ther; 2015 Jun; 32(6):485-95. PubMed ID: 26026272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.